Metabolic considerations of drugs in the treatment of allergic diseases

García‐Martín, Elena; Cantó, Gabriela; Agúndez, José A. G.

doi:10.1517/17425255.2013.823400

Cited by 4 publications

(4 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Impaired metabolism may cause drug accumulation with the associated adverse effects or it may cause therapeutic failure if prodrugs are not efficiently converted to their active forms. It has been shown that diverse Cytochrome P450 enzymes are involved in the metabolism of formoterol, and CYP3A4 and CYP3A5 are involved in the hydroxylation of salmeterol (revised in García-Martín et al, 2013). In this respect, CYP3A5 is the principal CYP3A form in the lung (Kivistö et al, 1996), and since the above-mentioned drugs suffer pre-systemic metabolism, it is plausible that patient carriers of the gain-of-function CYP3A5 * 1 allele may have lower bioavailability, or lower therapeutic efficacy, or apparent resistance, to inhaled drugs that are CYP3A substrates, but further studies to confirm this hypothesis are necessary (García-Martín et al, 2013).…”

Section: Drugs Used In Asthma Treatmentmentioning

confidence: 99%

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

Asthma is a frequent disease, mainly characterized by airway inflammation, in which drug therapy is crucial in its management. The potential of pharmacogenomics testing in asthma therapy has been, to date, little explored. In this review, we discuss pharmacogenetic factors affecting asthma treatment, both related to drugs used as controller medications for regular maintenance, such as inhaled corticosteroids, anti-leukotriene agents, long-acting beta-agonists, and the new biologic agents used to treat severe persistent asthma. In addition, we discuss current pharmacogenomics knowledge for rescue medications provided to all patients for as-needed relief, such as short-acting beta-agonists. Evidence for genetic variations as a factor related to drugs response has been provided for the following genes and groups of drugs: Inhaled corticosteroids: FCER2 ; anti-leukotriene agents: ABCC1 , and LTC4S ; beta-agonists: ADRB2 . However, the following genes require further studies confirming or rejecting association with the response to asthma therapy: ADCY9, ALOX5, ARG1, ARG2, CRHR1, CRHR2, CYP3A4, CYP3A5, CYSLTR1, CYSLTR2, GLCCI1, IL4RA, LTA4H, ORMDL3, SLCO2B1, SPATS2L, STIP1, T, TBX21, THRA, THRB , and VEGFA . Although only a minority of these genes are, at present, listed as associated with drugs used in asthma therapy, in the Clinical Pharmacogenomics Implementation Consortium gene-drug pair list, this review reveals that sufficient evidence to start testing the potential of clinical pharmacogenomics in asthma therapy already exists. This evidence supports the inclusion in pilot pharmacogenetics tests of at least four genes. Hopefully these tests, if proven useful, will increase the efficiency and the safety of asthma therapy.

show abstract

Section: Drugs Used In Asthma Treatmentmentioning

confidence: 99%

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Regarding Phase II enzymes, the most relevant in terms of percentage of drugs metabolized are UDP-glucuronyltransferases (UDPs), glutathione S -transferases (GSTs), sulphotransferases (SULTs), and N -acetyltransferases (NATs) particularly NAT2 ( Evans and Relling, 1999 ). Drugs belonging to many pharmacological groups are affected by polymorphic metabolism mediated by these enzymes, including for instance anesthetics, anti-Parkinson’s disease drugs, antihistamine drugs, antipsychotics, narcotics, or antidepressants; specific recommendations for the use of these drugs in the context of variability in drug metabolism have been published ( Restrepo et al, 2009 ; Khokhar and Tyndale, 2011 ; Relling and Klein, 2011 ; Swen et al, 2011 ; Agundez et al, 2013 ; Garcia-Martin et al, 2013 ).…”

Section: Enzymes That Metabolize Cns Drugsmentioning

confidence: 99%

Drug and xenobiotic biotransformation in the bloodâ€“brain barrier: a neglected issue

Agúndez¹,

Jiménez‐Jiménez²,

Alonso‐Navarro

et al. 2014

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Drug biotransformation is a crucial mechanism for facilitating the elimination of chemicals from the organism and for decreasing their pharmacological activity. Published evidence suggests that brain drug metabolism may play a role in the development of adverse drug reactions and in the clinical response to drugs and xenobiotics. The blood–brain barrier (BBB) has been regarded mainly as a physical barrier for drugs and xenobiotics, and little attention has been paid to the BBB as a drug-metabolizing barrier. The presence of drug-metabolizing enzymes in the BBB is likely to have functional implications because local metabolism may inactivate drugs or may modify the drug’s ability to cross the BBB, thus modifying drug response and the risk of developing adverse drug reactions. In this perspective paper, we discuss the expression of relevant xenobiotic metabolizing enzymes in the brain and in the BBB, and we cover current advances and future directions on the potential role of these BBB drug-metabolizing enzymes as modifiers of drug response.

show abstract

“…It is metabolized in the liver by oxidative processes, excreted mainly in the feces. Less than 5% of the drug (in the form of the parent substance or metabolites) is excreted in the urine [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…Praziquantel is metabolized in the liver by CYP3A enzymes to metabolites, the activity of which is not known. It is excreted mainly in the urine [3,[5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Determination of the timing of slaughter of sheep after the use of the drug MONIZEN^® forte

Engasheva

Dorozhkin

2021

BIO Web Conf.

View full text Add to dashboard Cite

The article is devoted to the results of determining the residual amounts of active ingredients of the medicinal product for veterinary use - MONISEN® forte - in the organs and tissues of sheep. MONISEN® forte is a solution for oral and parenteral use, the active ingredients include praziquantel and ivermectin. MONIZEN® forte is used for prophylactic and therapeutic purposes in small ruminants with cestodoses, nematodes of the lungs and gastrointestinal tract, trematodoses, estrosis, psoroptosis, chorioptosis, sarcoptosis, ixodidosis, sifunculatosis, and also melicophagoses, arachinoses, and biliary tract. Carrying out this study is mandatory for the introduction of the drug into wide industrial practice. As a result of the studies, the terms of slaughter of small ruminants after the use of the drug Monizen® forte were established. It is advisable to slaughter sheep for meat 35 days after the last use of the drug.

show abstract

Metabolic considerations of drugs in the treatment of allergic diseases

Cited by 4 publications

References 84 publications

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

Drug and xenobiotic biotransformation in the bloodâ€“brain barrier: a neglected issue

Determination of the timing of slaughter of sheep after the use of the drug MONIZEN^® forte

Contact Info

Product

Resources

About

Metabolic considerations of drugs in the treatment of allergic diseases

Cited by 4 publications

References 84 publications

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

Drug and xenobiotic biotransformation in the bloodâ€“brain barrier: a neglected issue

Determination of the timing of slaughter of sheep after the use of the drug MONIZEN® forte

Contact Info

Product

Resources

About

Determination of the timing of slaughter of sheep after the use of the drug MONIZEN^® forte